As of this September and for the next three years, the director of the Institute for Research in Biomedicine (IRB Barcelona), Joan J.
At 19 h on Tuesday 29 September, Ernest Giralt, coordinate of the Chemistry and Molecular Pharmacology Programme at the Institute for Research in Biomedicine (IRB Barcelona), group leader at the sa
This year the Asociación Española Contra el Cáncer (AECC)(Spanish Association against Cancer) is granting 6.7 million euros to fund four cutting-edge research projects.
On Tuesday 22 September, Carlos Romero, a 44-year-old telecom engineer from Sant Esteve Sesrovires, Barcelona, will swim across the Strait of Gibraltar in support of cancer and metastasis investi
Diario Médico & other media
Raúl Méndez, ICREA researcher and group leader of the Translational Control of Cell Cycle and Differentiation Laboratory at IRB Barcelona, has participated in a study led by Marcos Malumbres, from CNIO, in which a new anticancer strategy is proposed.
Nature Middle East
The journal Nature Middle East has interviewed Modesto Orozco, group leader at IRB Barcelona, Director of Life Sciences at the BSC-CNS, and Professor at the UB. Orozco talks about the recent publication in Nature Methods of a study on inntags, a new method developed in collaboration with CSIC, IRB Barcelona, BSC and UB to study proteins.
El Punt Avui & other media
Various media, including the newspaper “El Punt Avui”, have echoed the study published in PLoS Biology by Marco Milán, ICREA researcher and group leader of the Development and Growth Control Laboratory at IRB Barcelona, and Ana Ferreira, PhD student from the same laboratory.
«98% of the potential therapeutic molecules against diseases of the central nervous system cannot cross the blood-brain barrier. We develop peptides with the capacity to open the doors of the barrier and act as shuttles when attached to a therapeutic molecule.»
«Our study highlights the complexity of p38 functions, both in cancer and in the maintenance of normal tissues. It shows why an inhibitor of this molecule could effectively have undesirable side effects. But these do not exclude it from being a target against cancer.»
More on this news here.
Felice Alessio Bava
former PhD student in the Translational Control of Cell Cycle and Differentiation Lab
«We suspected that CPEB1, a protein involved in regulating mRNA translation in the cytoplasm, might also be active in the nucleus and play a role in controlling pre-mRNA processing. We discovered that it affects the alternative generation in the mature mRNA of the 3'-UTR, regions where most of the elements regulating translation in time and space are located.»
More info about this news here.
«Controlling a biological process from outside is the future of chemistry and opens up promising roads for advancements in pharmacological research.»
More info on this news here.
Quick facts about IRB
IRB Barcelona has been awarded the "HR Excellence in Research" logo. This recognition reflects the commitment of the Institute to continuously improving its human resources policies in line with the European Charter for Researchers and the Code of Conduct for the Recruitment of Researchers. The award confirms the efforts of the Institute to ensure fair and transparent recruitment and appraisal procedures. Click here for more information.
IRB Barcelona is home to nearly 450 research, technical and support staff from 35 countries who share the common goal of contributing to the advancement of the biomedical sciences through investigator–driven research, and improving quality of life by applying advances in this field.
The convergence of biology, chemistry, and structural and computational biology is unique at IRB Barcelona and opens a strategic window to gain insight into basic molecular processes in health and disease.
Research is conducted by 23 groups organized into 5 interdisciplinary programmes. Each programme includes a diverse faculty of researchers with overlapping scientific interests. The research areas have been structured to be highly interactive, fostering multidisciplinarity by combining modern molecular biology, classical genetics, biochemistry, structural biology, bioinformatics, systems biology, advanced microscopy, and genomic and proteomic approaches.